Frontera Therapeutics

Frontera Therapeutics

Edit info

  • Founded: 2019
  • Location: Bedford, MA
  • Employee range: 50 - 200
  • Clinical stage: Clin1
  • Therapy area: wAMD
  • Drug types: OPH, RAR, HEM, END, CVV, NEU
  • Lead product: FT-003
  • Funding: $160M B Jul 2022
  • Investors: OrbiMed, Boyu Capital Consultancy, Sequoia China, Creacion Ventures


fronteratherapeutics.com

linkedin.com

job board


Drug notes:

FT-001 Clin1 LCA2; FT-002 Clin1 X-linked retinitis pigmentosa; FT-004 Clin0 Hemophilia B; 4 add'l early stage products

About:

Frontera Therapeutics is developing cost-effective recombinant virus-based gene therapies across multiple disease areas. Using their APEX technology and manufacturing platform, Frontera is creating adeno-associated virus (AAV) gene expression systems to develop novel gene therapy products with quicker speed-to-market and lower cost. With their advanced technology, Frontera is building a pipeline that extends beyond monogenic diseases to indications in Ophthalmology, Hematology and Cardiovascular and Metabolic Diseases.

Jobs:

Post a job


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com